Structure via PubChem · Public domain (PubChem)
efinaconazole
Sign in to saveAlso known as (2R,3R)-2-(2,4-Difluorophenyl)-3-(4-methylene-1-piperidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol, KP-103
Efinaconazole, sold under the brand name Jublia and Clenafin among others, is a triazole antifungal compound discovered by Kaken Pharmaceutical, indicated for the treatment of onychomycosis, a fungal infection of the nail. Since it has low binding affinity with keratin, the main component of nails, it has superior nail-penetrating properties. It is approved for use in the United States, Canada, Japan and certain European countries as a 10% topical solution.
Chemical data
- Formula
- C18H22F2N4O
- Molecular weight
- 348.4 g/mol
- IUPAC name
- (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylidenepiperidin-1-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2014
- Admin. routes
- topical
- Indications
- tinea, tinea unguium
via ChEMBL · EBI
Research
281 papers- Efinaconazole in Onychomycosis.American journal of clinical dermatology · 2022
- Efinaconazole.2006
- Efinaconazole and Tavaborole.Journal of pharmacy practice · 2017
- Efinaconazole 10% solution: a comprehensive review of its use in the treatment of onychomycosis.Expert opinion on pharmacotherapy · 2024
- Efinaconazole topical solution (10%) for the treatment of onychomycosis in adult and pediatric patients.Expert review of anti-infective therapy · 2022
via PubMed
Wikidata facts
- Subclass of
- azole
- Mass
- 348.176168
- Has use
- medication
Show 6 more facts
- chemical formula
- C₁₈H₂₂F₂N₄O
- canonical SMILES
- CC(C(CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)N3CCC(=C)CC3
- isomeric SMILES
- C[C@H]([C@](CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)N3CCC(=C)CC3
- World Health Organisation international non-proprietary name
- efinaconazole
- subject has role
- antifungal
- Commons category
- Efinaconazole
Sources (2)
via Wikidata · CC0
~3 min read
Encyclopedic overview
6 sectionsContents
- Medical uses
- Efficacy
- History
- Economics
- References
- External links
Efinaconazole, sold under the brand name Jublia and Clenafin among others, is a triazole antifungal compound discovered by Kaken Pharmaceutical, indicated for the treatment of onychomycosis, a fungal infection of the nail. Since it has low binding affinity with keratin, the main component of nails, it has superior nail-penetrating properties. It is approved for use in the United States, Canada, Japan and certain European countries as a 10% topical solution.
Efinaconazole acts as a 14α-demethylase inhibitor.
Excerpted from Wikipedia’s “efinaconazole” article, available under the CC BY-SA 4.0 licence.